The company’s financial position saw a significant turnaround, with pro forma cash and marketable securities exceeding $310 million as of mid-2026. This liquidity provides the necessary cushion to advance its primary candidates, notably the BLA submission for the Duchenne muscular dystrophy therapy RGX-202, slated for the third quarter of this year. CEO Curran Simpson emphasized that the company is prepared to deliver on high-value catalysts, including pivotal wet AMD data expected in the final months of 2026.
In section Releases
REGENXBIO Extends Cash Runway Following Milestone-Driven Quarter
REGENXBIO secured over $200 million in fresh capital this July, bolstering its balance sheet into late 2027 as the biotech firm nears critical regulatory milestones for its gene therapy pipeline. The Rockville-based company reported a profitable second quarter, largely fueled by a $100 million payment from partner AbbVie.
Operational momentum remains high across its clinical programs. The confirmatory trial for RGX-202 met its primary endpoint with high statistical significance, and the company has already received FDA confirmation that no further studies are required for the resubmission of its Hunter syndrome treatment, NAVSUNLI. With manufacturing operations housed in-house, REGENXBIO is positioning itself to shift from clinical development toward commercial-readiness for its portfolio of rare and retinal disease therapies.
Comments (0)
No comments yet. Be the first!